CheckMate 8HW研究纳入人群与Keynote-177研究基本一致,根据此前公布的研究结果,帕博利珠单抗降低40%的疾病进展或死亡风险(HR 0.60),而NIVO联合IPI的双免方案降低了79%的疾病进展或死亡风险(HR 0.21),双免方案在一线应用中的价值不言而...
Experts discuss the CheckMate 8HW study, focusing on its design, key findings, and impact on treatment strategies.This is a modal window. This video is either unavailable or not supported in this browserError Code: MEDIA_ERR_SRC_NOT_SUPPORTED...
first results of the checkmate 8hw study 纳武利尤单抗(nivo)+依匹木单抗(ipi) vs.化疗(chemo)一线(1l)治疗微卫星高度不稳定/错配修复缺陷(msi-h/dmmr)转移性结直肠癌(mcrc):checkmate 8hw研究的第一个结果 背景 msi-h/dmmr...
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study. J Clin...
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary.
Dr. Heinz-Josef Lenz presents first results from the CheckMate 8HW trial, demonstrating that nivolumab plus ipilimumab significantly improves progression-free survival and overall response rates compared to nivolumab monotherapy in ...
CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with ...
LBA143#Background:The CheckMate 8HW study met its dual primary endpoint with NIVO + IPI demonstrating superior progression-free survival (PFS) by blinded independent central review (BICR) vs chemotherapy (chemo) in patients (pts) with centrally confirmed MSI-H/dMMR mCRC in the first-line (1L...
Summary Background CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free ...
2. A study of nivolumab, nivolumab plus ipilimumab, or investigator's choice chemotherapy for the treatment of participants with deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC) (CheckMate 8HW). ClinicalTrials.gov. Updated October 27, 2023...